MedTrace Logo

Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial

NCT04948749 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 792

Last updated 2024-12-27

No results posted yet for this study

Summary

The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.

Conditions

  • ICAD - Intracranial Atherosclerotic Disease
  • ICAS - Intracranial Atherosclerosis
  • Drug-eluting Stent
  • Stroke
  • Drug Eluting Stents (DES)
  • Medical Treatment

Interventions

DEVICE

Drug Eluting Stent implantation

The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.

DRUG

Aggressive medical treatment

Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).

BEHAVIORAL

Risk factor management

Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)

DRUG

Standard medical treatment

Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Yongjun Wang, MD · Beijing Tiantan Hospital

  • Zhongrong Miao, MD · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-02
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948749 on ClinicalTrials.gov